Cardiotoxicity of Radiation Therapy in Esophageal Cancer

Overview

Journal Rep Pract Oncol Radiother

Specialty Oncology

Date 2020 Mar 21

PMID 32194352

Citations 11

Authors

Milan Vosmik

Miroslav Hodek

David Buka

Petra Sykorova

Jakub Grepl

Petr Paluska

Simona Paulikova

Igor Sirak

Affiliations

Soon will be listed here.

Abstract

With a development of radiotherapeutic techniques, availability of radiotherapy data on cardiotoxicity, and slowly improving esophageal cancer outcomes, an increasing emphasis is placed on the heart protection in radiation treated esophageal cancer patients. Radiation induced heart complications encompass mainly pericardial disease, cardiomyopathy, coronary artery atherosclerosis, valvular heart disease, and arrhythmias. The most frequent toxicity is pericardial effusion which is usually asymptomatic in the majority of patients. The use of modern radiotherapy techniques is expected to reduce the risk of cardiotoxicity, although this expectation has to be confirmed by clinical data.

Citing Articles

Clinical outcomes and prognostic factors of volumetric modulated arc therapy (VMAT) of esophageal cancer.

Fukuzawa T, Nagao R, Kuroki T, Mikami T, Akiba T, Nakano Y Rep Pract Oncol Radiother. 2025; 29(4):426-436.

PMID: 39895953 PMC: 11785388. DOI: 10.5603/rpor.101529.

Narrative Review: Cardiotoxicities and Cardiac-Sparing Techniques in Radiotherapy.

Chan M, Parikh D, Shi C Technol Cancer Res Treat. 2024; 23:15330338241301211.

PMID: 39636079 PMC: 11622324. DOI: 10.1177/15330338241301211.

Treatment Strategies for Locoregional Recurrence in Esophageal Squamous-Cell Carcinoma: An Updated Review.

Mitamura A, Tsujinaka S, Nakano T, Sawada K, Shibata C Cancers (Basel). 2024; 16(14).

PMID: 39061179 PMC: 11274925. DOI: 10.3390/cancers16142539.

Consequences of ionizing radiation exposure to the cardiovascular system.

Jahng J, Little M, No H, Loo Jr B, Wu J Nat Rev Cardiol. 2024; 21(12):880-898.

PMID: 38987578 DOI: 10.1038/s41569-024-01056-4.

Development and validation of a nomogram to predict cardiac death after radiotherapy for esophageal cancer.

Lv X, Wu X, Liu K, Zhao X, Pan C, Zhao J Cancer Innov. 2023; 2(5):391-404.

PMID: 38090380 PMC: 10686179. DOI: 10.1002/cai2.89.

References

Fukada J, Shigematsu N, Takeuchi H, Ohashi T, Saikawa Y, Takaishi H . Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2013; 87(3):487-93. DOI: 10.1016/j.ijrobp.2013.07.008. View

Ling T, Slater J, Nookala P, Mifflin R, Grove R, Ly A . Analysis of Intensity-Modulated Radiation Therapy (IMRT), Proton and 3D Conformal Radiotherapy (3D-CRT) for Reducing Perioperative Cardiopulmonary Complications in Esophageal Cancer Patients. Cancers (Basel). 2014; 6(4):2356-68. PMC: 4276971. DOI: 10.3390/cancers6042356. View

Chen Y, Liu A, Han C, Tsai P, Schultheiss T, Pezner R . Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. Med Dosim. 2007; 32(3):166-71. DOI: 10.1016/j.meddos.2006.12.003. View

Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A . Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004; 53(7):925-30. PMC: 1774092. DOI: 10.1136/gut.2003.025080. View

Yusuf S, Venkatesulu B, Mahadevan L, Krishnan S . Radiation-Induced Cardiovascular Disease: A Clinical Perspective. Front Cardiovasc Med. 2017; 4:66. PMC: 5662579. DOI: 10.3389/fcvm.2017.00066. View

Prayongrat A, Xu C, Li H, Lin S . Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience. Adv Radiat Oncol. 2017; 2(3):301-307. PMC: 5605301. DOI: 10.1016/j.adro.2017.06.002. View

Hirano Y, Onozawa M, Hojo H, Motegi A, Zenda S, Hotta K . Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol. 2018; 13(1):23. PMC: 5807768. DOI: 10.1186/s13014-018-0966-5. View

Fakhrian K, Ordu A, Lordick F, Theisen J, Haller B, Omrcen T . Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU: more than 20 years' experience at a single institution. Strahlenther Onkol. 2014; 190(12):1133-40. DOI: 10.1007/s00066-014-0711-4. View

Urschel J, Vasan H . A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003; 185(6):538-43. DOI: 10.1016/s0002-9610(03)00066-7. View

10.

van Nimwegen F, Schaapveld M, Cutter D, Janus C, Krol A, Hauptmann M . Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. J Clin Oncol. 2015; 34(3):235-43. DOI: 10.1200/JCO.2015.63.4444. View

11.

Beukema J, van Luijk P, Widder J, Langendijk J, Muijs C . Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer?. Radiother Oncol. 2015; 114(1):85-90. DOI: 10.1016/j.radonc.2014.11.037. View

12.

Tait L, Meyer J, McSpadden E, Cheng J, Baciewicz F, Meropol N . Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinoma. Pract Radiat Oncol. 2014; 3(4):e149-55. DOI: 10.1016/j.prro.2013.02.001. View

13.

Wei X, Liu H, Tucker S, Wang S, Mohan R, Cox J . Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008; 70(3):707-14. DOI: 10.1016/j.ijrobp.2007.10.056. View

14.

Shiraishi Y, Xu C, Yang J, Komaki R, Lin S . Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy. Radiother Oncol. 2017; 125(1):48-54. DOI: 10.1016/j.radonc.2017.07.034. View

15.

Gharzai L, Verma V, Denniston K, Bhirud A, Bennion N, Lin C . Radiation Therapy and Cardiac Death in Long-Term Survivors of Esophageal Cancer: An Analysis of the Surveillance, Epidemiology, and End Result Database. PLoS One. 2016; 11(7):e0158916. PMC: 4948887. DOI: 10.1371/journal.pone.0158916. View

16.

Worni M, Castleberry A, Gloor B, Pietrobon R, Haney J, DAmico T . Trends and outcomes in the use of surgery and radiation for the treatment of locally advanced esophageal cancer: a propensity score adjusted analysis of the surveillance, epidemiology, and end results registry from 1998 to 2008. Dis Esophagus. 2013; 27(7):662-9. PMC: 3923844. DOI: 10.1111/dote.12123. View

17.

Ruppert B, Watkins J, Shirai K, Wahlquist A, Garrett-Mayer E, Aguero E . Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol. 2009; 33(4):346-52. DOI: 10.1097/COC.0b013e3181aaca26. View

18.

Xie S, Lagergren J . Risk factors for oesophageal cancer. Best Pract Res Clin Gastroenterol. 2018; 36-37:3-8. DOI: 10.1016/j.bpg.2018.11.008. View

19.

Sekii S, Ito Y, Harada K, Kitaguchi M, Takahashi K, Inaba K . Intrafraction esophageal motion in patients with clinical T1N0 esophageal cancer. Rep Pract Oncol Radiother. 2018; 23(5):398-401. PMC: 6097394. DOI: 10.1016/j.rpor.2018.07.013. View

20.

Mathieu L, Kanarek N, Tsai H, Rudin C, Brock M . Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008). Dis Esophagus. 2013; 27(8):757-63. PMC: 3979505. DOI: 10.1111/dote.12147. View